In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
Binding of growth factors and cytokines to their cognate receptors on cell membranes triggers their endocytosis and degradation in lysosomes, thus providing a physiologically important negative feedback mechanism for cell signalling.
The ESCRT-II complex recognizes ubiquitinated receptors in the endosomal membrane, thus initiating their sorting to degradative lysosomes. (click to enlarge image)It is not known in detail how endocytosed receptors are trafficked to the degradative lysosomes, but work in Harald StenmarkÂ’s lab has uncovered several factors involved in this process. Among these are the so-called endosomal sorting complexes required for transport (ESCRTs), and Thomas Slagsvold in StenmarkÂ’s group has previously shown that the so-called GLUE domain in the ESCRT-II complex binds ubiquitin .
In a recent paper in Traffic, Lene Malerød, a postdoc in Stenmark’s lab, shows that the ESCRT-II complex is required for degradation of ubiquitinated epidermal growth factor receptor and chemokine receptors. This provides new insight into how growth factor and chemokine receptors are transported intracellularly and identifies a novel potential tumour suppressor complex.
From major journals, first or last author from the Institute for Cancer Research
Kuzu OF, Granerud LJT, Saatcioglu F(2025) Navigating the landscape of protein folding and proteostasis: from molecular chaperones to therapeutic innovations Signal Transduct Target Ther, 10(1), 358 DOI 10.1038/s41392-025-02439-w, PubMed 41130962
Rusten TE(2025) Autophagy regulation by signaling Curr Opin Cell Biol, 97, 102595(in press) DOI 10.1016/j.ceb.2025.102595, PubMed 41086756
Høyvik AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, Peng Q, Wangen-Riise R, Wiig E, Ma LW, Revheim ME, Juzeniene A(2025) Optimizing [212Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts J Nucl Med(in press) DOI 10.2967/jnumed.125.270444, PubMed 41043994
Pharo H, Brandt-Winge S, Thorkildsen EM, Vedeld HM, Lind GE(2026) DNA Methylation Analyses of Tissue Samples and Cell-Free DNA by Droplet Digital PCR Methods Mol Biol, 2969, 179-193 DOI 10.1007/978-1-0716-4767-7_12, PubMed 41073866
Emaldi M, Rey-Iborra E, Alamillo-Maeso P, Pulido R, Nunes-Xavier CE(2026) Analysis of the Functional Impact of Glycosylation on Immune Checkpoint Proteins Methods Mol Biol, 2959, 55-72 DOI 10.1007/978-1-0716-4734-9_4, PubMed 41028258
Rey-Iborra E, Emaldi M, Madariaga M, Pulido R, Nunes-Xavier CE(2026) 3D Spheroids to Study the Impact of Immune Checkpoint Proteins in Solid Tumors Methods Mol Biol, 2959, 141-156 DOI 10.1007/978-1-0716-4734-9_10, PubMed 41028264